Sana narrows focus to ex vivo cell therapies, lays off 29% of staff to reach key clinical data
Sana Biotechnology will let go about 29% of its staff, or roughly 120 employees, to focus on its ex vivo cell therapies, according to a source familiar with the decision.
The Seattle biotech said the cost-cutting, announced after Tuesday’s closing bell, will help it conserve cash so it can bankroll four cell therapies to clinical readouts later this year and in 2024. In August, Endpoints News reported that Sana had let go an undisclosed number of employees in “a single area of research.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
